TY - JOUR
T1 - Impact of cord blood banking technologies on clinical outcome
T2 - a Eurocord/Cord Blood Committee (CTIWP), European Society for Blood and Marrow Transplantation and NetCord retrospective analysis
AU - Saccardi, Riccardo
AU - Tucunduva, Luciana
AU - Ruggeri, Annalisa
AU - Ionescu, Irina
AU - Koegler, Gesine
AU - Querol, Sergio
AU - Grazzini, Giuliano
AU - Lecchi, Lucilla
AU - Nanni Costa, Alessandro
AU - Navarrete, Cristina
AU - Pouthiers, Fabienne
AU - Larghero, Jerome
AU - Regan, Donna
AU - Freeman, Taryn
AU - Bittencourt, Henrique
AU - Kenzey, Chantal
AU - Labopin, Myriam
AU - Baudoux, Etienne
AU - Rocha, Vanderson
AU - Gluckman, Eliane
PY - 2016/8/1
Y1 - 2016/8/1
N2 - BACKGROUND: Techniques for banking cord blood units (CBUs) as source for hematopoietic stem cell transplantation have been developed over the past 20 years, aimed to improve laboratory efficiency without altering the biologic properties of the graft. A large-scale, registry-based assessment of the impact of the banking variables on the clinical outcome is currently missing. STUDY DESIGN AND METHODS: A total of 677 single cord blood transplants (CBTs) carried out for acute leukemia in complete remission in centers affiliated with the European Society for Blood and Marrow Transplantation were selected. An extensive set of data concerning CBU banking were collected and correlations with clinical outcome were assessed. Clinical endpoints were transplant-related mortality, engraftment, and graft-versus-host disease (GVHD). RESULTS: The median time between collection and CBT was 4.1 years (range, 0.2-16.3 years). Volume reduction (VR) of CBUs before freezing was performed in 59.2% of available reports; in half of these the frozen volume was less than 30 mL. Cumulative incidences of neutrophil engraftment on Day 60, 100-day acute GVHD (II-IV), and 4-year chronic GVHD were 87, 29, and 21 ± 2%. The cumulative incidence of nonrelapse mortality (NRM) at 100 days and 4-year NRM were, respectively, 16 ± 2 and 30 ± 2%. Neither the variables related to banking procedures nor the interval between collection and CBT influenced the clinical outcome. CONCLUSION: These findings indicate a satisfactory validation of the techniques associated with CBU VR across the banks. Cell viability assessment varied among the banks, suggesting that efforts to improve the standardization of CBU quality controls are needed.
AB - BACKGROUND: Techniques for banking cord blood units (CBUs) as source for hematopoietic stem cell transplantation have been developed over the past 20 years, aimed to improve laboratory efficiency without altering the biologic properties of the graft. A large-scale, registry-based assessment of the impact of the banking variables on the clinical outcome is currently missing. STUDY DESIGN AND METHODS: A total of 677 single cord blood transplants (CBTs) carried out for acute leukemia in complete remission in centers affiliated with the European Society for Blood and Marrow Transplantation were selected. An extensive set of data concerning CBU banking were collected and correlations with clinical outcome were assessed. Clinical endpoints were transplant-related mortality, engraftment, and graft-versus-host disease (GVHD). RESULTS: The median time between collection and CBT was 4.1 years (range, 0.2-16.3 years). Volume reduction (VR) of CBUs before freezing was performed in 59.2% of available reports; in half of these the frozen volume was less than 30 mL. Cumulative incidences of neutrophil engraftment on Day 60, 100-day acute GVHD (II-IV), and 4-year chronic GVHD were 87, 29, and 21 ± 2%. The cumulative incidence of nonrelapse mortality (NRM) at 100 days and 4-year NRM were, respectively, 16 ± 2 and 30 ± 2%. Neither the variables related to banking procedures nor the interval between collection and CBT influenced the clinical outcome. CONCLUSION: These findings indicate a satisfactory validation of the techniques associated with CBU VR across the banks. Cell viability assessment varied among the banks, suggesting that efforts to improve the standardization of CBU quality controls are needed.
UR - http://www.scopus.com/inward/record.url?scp=84982999619&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84982999619&partnerID=8YFLogxK
U2 - 10.1111/trf.13661
DO - 10.1111/trf.13661
M3 - Article
C2 - 27245270
AN - SCOPUS:84982999619
VL - 56
SP - 2021
EP - 2029
JO - Transfusion
JF - Transfusion
SN - 0041-1132
IS - 8
ER -